Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy

Authors

  • İlker Selçuk Gynecologic Oncology Unit Zekai Tahir Burak Women’s Health, Education and Research Hospital, Ankara
  • İpek Düzgüner Gynecologic Oncology Unit, Etlik Zubeyde Hanım Women Diseases, Education and Research Hospital, Ankara
  • Sevda Baş Gynecologic Oncology Unit Zekai Tahir Burak Women’s Health, Education and Research Hospital, Ankara
  • Taner Turan Gynecologic Oncology Unit, Etlik Zubeyde Hanım Women Diseases, Education and Research Hospital, Ankara
  • Afra Alkan Department of Biostatistics, Yıldırım Beyazit University Faculty of Medicine, Ankara
  • Nurettin Boran Gynecologic Oncology Unit, Etlik Zubeyde Hanım Women Diseases, Education and Research Hospital, Ankara
  • Mehmet Mutlu Meydanlı Gynecologic Oncology Unit Zekai Tahir Burak Women’s Health, Education and Research Hospital, Ankara
  • Gökhan Tulunay Gynecologic Oncology Unit, Etlik Zubeyde Hanım Women Diseases, Education and Research Hospital, Ankara

Keywords:

Ovarian carcinosarcoma, Chemotheraphy, Survival, Platinum, Doxorubicin

Abstract

OBJECTIVE: To analyse the survival outcomes of women with ovarian carcinosarcoma according to platinum or doxorubicin based adjuvant chemotherapy protocols.

STUDY DESIGN: This retrospective study was performed at Etlik Zübeyde Hanım and Zekai Tahir Burak Women’s Health Education and Research Hospitals, which are tertiary centers in Turkey. A total of 31 women with ovarian carcinosarcoma between January 1999 and January 2013 were evaluated retrospectively.

RESULTS: The mean age of patients was 53.84±10.13. Most of the patients were diagnosed with stage IIIC ovarian carcinosarcoma (n=21, 67.7%). Maximal debulking and optimal debulking was performed to 23 (74.2%) and 8 (25.8%) patients, respectively. Disease free survival was significantly shorter in stage IIIC patients when compared to stage IIIB patients (p=0.048). Disease free survival for one and three years according to the treatment protocol (platinum or doxorubicin based) was not significantly different (p=0.574). Additionally, three and five years overall survival was not significantly different (p=0.891) between the platinum and doxorubicin based chemotherapy protocols.

DISCUSSION: We did not find a significant difference in terms of disease free survival and overall survival between platinum and doxorubicin based adjuvant chemotherapy protocols in women with ovarian carcinosarcoma.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Downloads

Published

2015-04-30

How to Cite

1.
Selçuk İlker, Düzgüner İpek, Baş S, Turan T, Alkan A, Boran N, Meydanlı MM, Tulunay G. Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy. Gynecol Obstet Reprod Med [Internet]. 2015Apr.30 [cited 2021Mar.7];21(1):36-40. Available from: https://www.gorm.com.tr/index.php/GORM/article/view/43

Issue

Section

Gynecology and Gynecological Oncology

Most read articles by the same author(s)

1 2 3 4 > >>